In the ever-evolving realm of healthcare and pharmaceuticals, the intricate dance between innovation and investment shapes the trajectory of groundbreaking discoveries and patient-centric a
Patient centricity has been a key focus for pharma in 2023. However, extending beyond the merely discursive topic into sustained and tangible action at scale has been somewhat limited.
For many spin-outs and start-ups in the pharmaceutical space, a key step in getting their science into patients is teaming up with a larger pharmaceutical company.
For pharmaceutical companies and other healthcare stakeholders, it is imperative that they understand how patient experience and input needs to be captured, contextualised, and applied to t
At DPHARM 2023 in Boston, Pfizer announced that it has taken the first steps towards sharing clinical trial participants’ own data with them – something participants have sought for years.<
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.